Sygnature Discovery

MARCH 7, 2023

Sygnature Discovery, the global integrated drug discovery company, has unveiled a new platform that facilitates the combinational high-throughput assembly and review of molecular degraders ( CHARMED ), in response to a sustained rise in demand for its multi-disciplinary expertise. What is the CHARMED platform?

Targeted Protein Degradation 52

Targeted Protein Degradation DNA Engineering Drugs 52

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 1 However, efforts proved less effective than the original drugs, owing mostly to insufficient toxicity against cancer cells.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

LifeSciVC

FEBRUARY 5, 2025

While the successful therapeutic targeting of transcription factors is a relatively new undertaking by industry, these proteins themselves are nothing new. Given this ever-increasing body of evidence, why is it that for so long, they have not been the focus of drug discovery?

Small Molecule 67

Small Molecule Targeted Protein Degradation Regulations Disease 67